An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Rybelsus is a GLP-1 receptor agonist drug that's prescribed to treat type 2 diabetes in adults. Learn the key facts you should know about this medication before taking it.

Rybelsus (Semaglutide) Cost and Financial Assistance Medically reviewed by Victor Nguyen, PharmD, MBA — Written by Alex Brewer, PharmD, MBA — Updated on June 11, 2025 Cost and savings ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION per the EU drug regulator. Read more here.

GLP-1 receptor agonist semaglutide significantly outperformed placebo in an ongoing phase 3 trial, showing reductions in steatohepatitis and liver fibrosis, in addition to cardiometabolic benefits.

Novo Nordisk’s semaglutide patent battle a test case Novo Nordisk is locked in a patent infringement battle with Dr Reddy’s Laboratories and OneSource Specialty Pharma By PT Jyothi Datta ...

Semaglutide is marketed under the brand names Wegovy ® (semaglutide) injection 2.4 mg, Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, and Rybelsus ® (semaglutide) tablets 7 mg or 14 ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

Media: Ambre James-Brown +45 3079 9289... Liz Skrbkova (US) +1 609 917 0632... Investors: Jacob Martin Wiborg Rode +45 3075 5956... Ida Schaap Melvold ...

Up to 20 biosimilar or generic copies will vie for market share and add pricing pressure after Denmark-based Novo Nordisk’s semaglutide product loses patent protection in China next year ...